After Gilead Sciences dropped an ambiguous line for Trodelvy’s performance in HR-positive, HER2-negative breast cancer in March, all eyes are on this weekend's data presentation. And those detailed results don’t exactly meet doctors’ expectations.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,